论文部分内容阅读
为了解肝癌细胞增殖动力学特性对抗癌药物敏感性的影响程度,为临床合理使用抗癌药物提供理论依据,本研究应用细胞周期流式细胞仪(FCM)分析技术和抗癌药物敏感性体外同位素掺入法测定技术。对29例人体肝癌的细胞周期的数量比例与8种抗癌药物的敏感性进行了对比研究。结果显示,有22例肝癌(75.9%)对化疗药物敏感,单个抗癌药物有效率越高,其肝癌的细胞周期比例越与此相近,表明细胞周期比例在很大程度上参与对抗癌药物敏感性的影响。本文研究结果提示,FCM方法对细胞周期比例分析可从细胞核酸代谢及增殖动力学的角度,了解肿瘤细胞增殖特性与抗癌药物敏感性的关系,并提示了各种抗癌药物对肿瘤细胞不同的杀伤机理,认为FCM细胞周期分析可为提示肝癌的抗癌药物敏感性提供有临床实用价值的客观指标:为科学、合理、有效的制定个体化治疗方案开辟了新的途径。
To understand the effect of the proliferation kinetics of hepatocellular carcinoma on the anticancer drug susceptibility, provide theoretical basis for the rational use of anticancer drugs in clinic. This study uses cell cycle flow cytometry (FCM) analysis technology and anticancer drug sensitivity in vitro. Isotope incorporation assay technique. A comparative study was conducted on the ratio of the number of cell cycle of human liver cancer and the sensitivity of 8 anticancer drugs. The results showed that 22 cases of hepatocellular carcinoma (75.9%) were sensitive to chemotherapeutic drugs, and the higher the single anticancer drug was, the more similar the cell cycle ratio of liver cancer was, indicating that the proportion of cell cycle was largely involved in anticancer drugs. The effect of sensitivity. The results of this study suggest that FCM analysis of the cell cycle ratio can understand the relationship between the proliferation characteristics of cancer cells and the sensitivity of anticancer drugs from the perspective of cell nucleic acid metabolism and proliferation kinetics, and suggests that various anticancer drugs are different from tumor cells. The mechanism of killing, that FCM cell cycle analysis can provide an objective indicator of clinical utility value for the anti-cancer drug sensitivity of liver cancer: to open up a new way for scientific, rational and effective formulation of individualized treatment plan.